NuVasive Cuts Q3 Prelim Revenue, Forecast $147M
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today preliminary unaudited information regarding expected revenue results for the third quarter 2012. NuVasive anticipates revenue for the third quarter 2012 to be approximately $147 million, which is below the Company's previous comments that suggested flat sequential revenue growth compared to $154.4 million in the second quarter 2012.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.